[HTML][HTML] Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
LA de Jong, J Groeneveld, J Stevanovic, H Rila… - PLoS …, 2019 - journals.plos.org
Introduction Randomized clinical trials (RCTs) and real-world data (RWD) in patients with
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …
Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
LA de Jong, J Groeneveld, J Stevanovic, H Rila… - PloS …, 2019 - pubmed.ncbi.nlm.nih.gov
Introduction Randomized clinical trials (RCTs) and real-world data (RWD) in patients with
atrial fibrillation have shown that-compared to vitamin K antagonists (VKAs)-non-VKA oral …
atrial fibrillation have shown that-compared to vitamin K antagonists (VKAs)-non-VKA oral …
Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
LA de Jong, J Groeneveld, J Stevanovic, H Rila… - PLOS ONE, 2019 - ideas.repec.org
Introduction: Randomized clinical trials (RCTs) and real-world data (RWD) in patients with
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …
[引用][C] Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
LA de Jong, J Groeneveld, J Stevanovic, H Rila… - PLoS …, 2019 - ui.adsabs.harvard.edu
Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation
in the real-world and trial settings - NASA/ADS Now on home page ads icon ads Enable full …
in the real-world and trial settings - NASA/ADS Now on home page ads icon ads Enable full …
[PDF][PDF] Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
LA de Jong, J Groeneveld, J Stevanovic… - PLoS …, 2019 - pdfs.semanticscholar.org
Randomized clinical trials (RCTs) and real-world data (RWD) in patients with atrial
fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …
fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …
Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
LA de Jong, J Groeneveld, J Stevanovic, H Rila… - PLoS ONE, 2019 - go.gale.com
Introduction Randomized clinical trials (RCTs) and real-world data (RWD) in patients with
atrial fibrillation have shown that-compared to vitamin K antagonists (VKAs)-non-VKA oral …
atrial fibrillation have shown that-compared to vitamin K antagonists (VKAs)-non-VKA oral …
[PDF][PDF] Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
G Tieleman, MV Huisman, MJ Postma, M van Hulst - 2019 - core.ac.uk
Randomized clinical trials (RCTs) and real-world data (RWD) in patients with atrial
fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …
fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …
Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.
LA de Jong, J Groeneveld, J Stevanovic, H Rila… - PLoS …, 2019 - search.ebscohost.com
Abstract Introduction: Randomized clinical trials (RCTs) and real-world data (RWD) in
patients with atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs) …
patients with atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs) …
Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
LA de Jong, J Groeneveld, J Stevanovic, H Rila… - PLoS ONE, 2019 - research.rug.nl
INTRODUCTION: Randomized clinical trials (RCTs) and real-world data (RWD) in patients
with atrial fibrillation have shown that-compared to vitamin K antagonists (VKAs)-non-VKA …
with atrial fibrillation have shown that-compared to vitamin K antagonists (VKAs)-non-VKA …
Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
LA de Jong, J Groeneveld, J Stevanovic, H Rila… - PLOS …, 2019 - econpapers.repec.org
Introduction: Randomized clinical trials (RCTs) and real-world data (RWD) in patients with
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …